W.L. Gore - Delaware Business Times

Bioscience and pharmaceutical, Economic Development, Health Care, Manufacturing & Distribution, New Castle County, News

Gore acquires dialysis med-tech company

Jacob Owens September 7, 2022

FLAGSTAFF, Ariz. – W. L. Gore & Associates, a global material science company headquartered in Newark, recently acquired a small medical technology company focused on easing the treatment of dialysis patients. InnAVasc Medical, headquartered about ...

0 Comment 370 Views

Economic Development, Insider Only, News, Transportation

🔒 🔒 D2 proposes large Glasgow logistics park

Jacob Owens February 25, 2021

GLASGOW – A new proposal by the D2 Organization to develop an aborted W. L. Gore tract may bring more than 1 million square feet of distribution or industrial space to the Glasgow area. The ...

0 Comment 875 Views

Health Care, Manufacturing & Distribution, News, Technology & IT

Mayo Clinic, W.L. Gore announce stem cell venture

Jacob Owens December 10, 2019

NEWARK — W.L. Gore & Associates Inc. and Mayo Clinic have formed a joint venture that will seek to create a product that utilizes stem cells to treat a painful condition connected to Crohn’s disease. ...

0 Comment 1116 Views

News, Stuff, Technology & IT

Delaware’s vast and lasting contribution to NASA’s 1969 moon landing

Michael Bradley July 8, 2019

By Michael Bradley Contributing Writer If you happened to drive past the Dover High School football field in 1962, you might have noticed a man dressed in a spacesuit running and throwing a football, while ...

0 Comment 955 Views

Innovation Delaware: Chemistry

Editorial June 10, 2019

Dora Cheatham has a pretty simple explanation for what Delaware’s chemistry sector was like pre-2000. “It used to be just DuPont,” says Cheatham, the operations manager for the Delaware Sustainable Chemistry Alliance. Not long after ...

0 Comment 580 Views

Premier Digital Partners

© 2022 Delaware Business Times

[caption id="attachment_225707" align="aligncenter" width="1200"]

W. L. Gore & Associates recently acquired med-tech company InnAVasc Medical to complement its dialysis products. | DBT PHOTO BY JACOB OWENS[/caption] FLAGSTAFF, Ariz. – W. L. Gore & Associates, a global material science company headquartered in Newark, recently acquired a small medical technology company focused on easing the treatment of dialysis patients. InnAVasc Medical, headquartered about two hours north of Phoenix, focuses on improving care for patients with end-stage renal disease who utilize graft circuits, or surgically created connections between an artery and vein, for dialysis treatment. The terms of the deal announced Aug. 12 between the two private companies were not disclosed. Developed by Dr. Jeffrey Lawson and physician assistant Shawn Gage in the Duke University School of Medicine’s Department of Surgery, the InnAVasc device is “specifically designed to allow for safe, easy, reproducible and durable access for dialysis treatment of patients with graft circuits.” The investigational device is designed to protect the graft from accidental punctures and reduce the damage associated with frequent needle sticks that occur over the lifespan of a dialysis graft. This can lead to circuit failure and shortened circuit life. “To be stuck with two needles three times a week for hemodialysis for 52 weeks, that's 312 times a needle goes into a patient’s graft each year,” said Dr. Stephen Hohmann, vascular surgeon at Texas Vascular Associates, in a statement announcing the deal. “So having a graft that has the ability to decrease risk potential and long-term injury is definitely something that would be a game-changer.” InnAVasc’s device is currently in clinical trials and is not available for commercial use. It will complement Gore’s product line, which includes medical devices that treat a range of cardiovascular and other health conditions, including a vascular graft used in kidney disease made from its proprietary expanded polytetrafluoroethylene, or ePTFE. “The addition of InnAVasc’s investigational technology bolsters our continued ambition to improve patients’ lives by offering physicians innovative treatment solutions within the dialysis access space,” said Eric Zacharias, leader of Gore’s Medical Products Division, in a statement. “We are excited about InnAVasc’s unique technology and its potential to advance patient care for those with end-stage renal disease. This acquisition reinforces Gore’s commitment to innovation and desire to be strong partners in advancing treatments for these patients.” InnAVasc CEO Joseph Knight said his company sees “an array of synergies working with Gore.” “The company is well recognized for its advanced material capabilities. Its long history of designing graft solutions for many treatment challenges already includes the Gore Propaten and Acuseal vascular grafts, used in dialysis access procedures today, and we are excited to collaborate on future innovations. Together we aspire to significantly advance patient outcomes and improve dialysis treatment for patients with end-stage renal disease,” he said in a statement.